AQUESTIVE THERAPETC ($AQST) posted quarterly earnings results on Monday, May 12th. The company reported earnings of -$0.24 per share, missing estimates of -$0.17 by $0.07. The company also reported revenue of $8,720,000, missing estimates of $12,475,110 by $-3,755,110.
You can see Quiver Quantitative's $AQST stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
AQUESTIVE THERAPETC Insider Trading Activity
AQUESTIVE THERAPETC insiders have traded $AQST stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $AQST stock by insiders over the last 6 months:
- CASSIE JUNG (Chief Operating Officer) sold 44 shares for an estimated $214
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AQUESTIVE THERAPETC Hedge Fund Activity
We have seen 57 institutional investors add shares of AQUESTIVE THERAPETC stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VR ADVISER, LLC removed 2,925,769 shares (-52.7%) from their portfolio in Q4 2024, for an estimated $10,415,737
- INVESCO LTD. removed 738,635 shares (-93.9%) from their portfolio in Q4 2024, for an estimated $2,629,540
- FRANKLIN RESOURCES INC removed 631,746 shares (-22.8%) from their portfolio in Q4 2024, for an estimated $2,249,015
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 623,310 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $1,807,599
- BANK OF AMERICA CORP /DE/ added 621,614 shares (+905.2%) to their portfolio in Q4 2024, for an estimated $2,212,945
- PALE FIRE CAPITAL SE added 501,756 shares (+2090.7%) to their portfolio in Q4 2024, for an estimated $1,786,251
- CITADEL ADVISORS LLC removed 490,155 shares (-56.2%) from their portfolio in Q4 2024, for an estimated $1,744,951
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AQUESTIVE THERAPETC Analyst Ratings
Wall Street analysts have issued reports on $AQST in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 03/07/2025
- Alliance Global Partners issued a "Buy" rating on 03/07/2025
- Cantor Fitzgerald issued a "Overweight" rating on 12/17/2024
To track analyst ratings and price targets for AQUESTIVE THERAPETC, check out Quiver Quantitative's $AQST forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
